2021

Professional development Vacancies
2021
SIGNAL Uppsala Monitoring Centre Tocilizumab and pancreatitis (according to the WHO global database VigiBase)

Tocilizumab is a humanized monoclonal antibody against interleukin-6 (IL-6) and is prescribed for the treatment of rheumatoid arthritis, as well as some other forms of arthritis….

Read more
The benefit of medicinal products containing ifosfamide as solutions for infusion continues to outweigh the risks

The PRAC committee has concluded that the benefit of ifosfamide infusion solutions continues to outweigh the risks in the treatment of various types of malignant neoplasms, including…

Read more
Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of February 8-11, 2021

medicinal products containing prednisolone, prednisone – bradycardia Having considered the available evidence, including data provided by registration certificate holders, the PRAC committee agreed,…

Read more
Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting on 11-14 January 2021

medicinal products containing adalimumab – abnormal weight gain Having reviewed the available evidence from EudraVigilance and the literature, as well as clinical trial data…

Read more
Gilenya (fingolimod) and the risk of liver injury and herpes meningoencephalitis – recommendations of Health Canada and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA)

Gilenya (fingolimod) is indicated as monotherapy for the treatment of adults with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations and delay…

Read more
Medicinal products containing ulipristal acetate for uterine fibroids – EMA recommends restricting use

On November 12, 2020, the CHMP recommended restricting the use of medicinal products containing ulipristal acetate 5 mg (Esmya and generic…

Read more
Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of 23-26 November 2020

medicinal products containing pembrolizumab – vasculitis Having reviewed the available evidence from EudraVigilance and in the literature, as well as the relationship between the use of pembrolizumab…

Read more
Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of 23-26 November 2020

medicinal products containing chloroquine, hydroxychloroquine – psychiatric disorders Based on the review of data on the risk of psychiatric disorders with the use of chloroquine…

Read more
Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of 23-26 November 2020

medicinal products containing capecitabine – anaphylactic reactions Having reviewed the available evidence from EudraVigilance and in the literature, as well as the relationship of the medicinal products,…

Read more